Drug recall: Kanjo homeopathic pain relief cream with arnica due to manufacturing deviations
Homeocare Laboratories recalls Kanjo Homeopathic Pain Relief Cream due to manufacturing process deviations. The recall affects 921 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries and a theoretical manufacturing process hazard qualifies as Moderate under the rubric. The recall was voluntarily initiated by the firm.
Plain-English summary
Homeocare Laboratories, Inc. is recalling Kanjo Homeopathic Pain Relief Cream With Arnica (NDC 80551-201-02) due to deviations from current Good Manufacturing Practice (cGMP) standards. The affected product is the 2 oz (56.70G) size with lot number 2446 and an expiration date of March 2024.
The product was distributed nationwide across the United States. A total of 921 bottles were affected by this recall.
Consumers who have purchased this product should stop using it. The recall was voluntarily initiated by the firm on June 5, 2023, and was classified as a Class II recall by the FDA on June 26, 2023. The recall was terminated on September 16, 2024.
The recalled product
- Product
- Kanjo Homeopathic Pain Relief Cream With Arnica, NET WT 2 oz (56.70G), Manufactured For: Acutens, Inc., Sheridan, WY NDC 80551-201-02
- Manufacturer
- Homeocare Laboratories, Inc.
- Category
- Drug — Homeopathic / Topical
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 2446
- exp. date Mar-24
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27